Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)

• Status: Unknown status
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy and safety of procaterol hydrochloride with inhaled glucocorticoid in treatment patients with cough variant asthma (CVA).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Procaterol

Criteria

Inclusion Criteria:

• male or female patients,18-75 years old;

• cough lasting over 3 weeks ; dry cough or with slight white mucous phlegm; cough is the main clinical symptom or the only symptom;

• without wheeze and fever;

• without the history of upper respiratory tract infection within recent two months; non-smoking or giving-up smoking for over two years;

• without rales from lung;

• no obvious abnormalities from chest X-ray;

• bronchial provocation test: positive.

Exclusion Criteria:

• patients with chronic pulmonary disease;

• patients who are allergic to ß2 receptor agonist;

• patients taking ß2 receptor agonist for long time;

• severe heart, renal and hepatic disease;

• unable to comply with the protocol;

• pregnant, breast feeding, and childbearing potential women;

• patients improper to the trial according to the investigators' judgment.